Fig. 3

IL-17A downregulates CXCR3 expression on CD8⁺ T cells. a The expression of 13 cytokines in the sera of CRC patients (CRC-sera) vs. HD (HD-sera), sera of advanced-stage (advanced-sera) vs. early-stage CRC patients (early-sera), and supernatants of tumor tissues (tumor-sup) vs. normal tissues (normal-sup) were analyzed by multiplex assays. Fold changes were calculated with concentrations normalized with log2. b The intersection of the screened cytokines (fold changes ≥ 2) from a (red circle), b (blue circle), and c (green circle) of Fig. 3a. c FACS analysis of CXCR3⁺CD8⁺ T cell expression in CD8⁺ T cells treated with recombinant human proteins (20 ng/mL IL-17A, 20 ng/mL IL-17F, or 10 ng/mL IFN-γ) for 48 h. Each line represented a different HD. d Purified CD8⁺ T cells treated with or without rhIL-17A were subjected to immunofluorescence for CXCR3 (red) and DAPI (blue). e, f Concentrations of IL-17A (pg/mL) in sera obtained from CRC patients and HDs were measured using ELISA. g Correlation between the concentration of IL-17A and the percentage of CXCR3⁺CD8⁺ T cells in CD8⁺ T cells. Data were analyzed by Spearman’s rank correlation. *P < 0.05, NS non-significant